Antibodies News and Research

RSS

Impaired immune response to SARS-CoV-2 mRNA vaccination in immunocompromised patients

A new study describes how immunocompromised vaccine recipients may not always respond as expected to the COVID-19 vaccine.

27 Jul 2021

PerkinElmer to Acquire Antibody and Reagent Leader BioLegend

PerkinElmer, Inc. today announced it has entered into an agreement to acquire BioLegend, a leading, global provider of life science antibodies and reagents.

From Revvity 27 Jul 2021

Monoclonal antibody CT-P59 demonstrates potent antiviral efficacy against SARS-CoV-2 delta variant

A Korean study has recently demonstrated antiviral potency of monoclonal antibody CT-P59 against the delta variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The experiments conducted in animals infected with the delta variant have shown that CT-P59 is able to reduce symptom intensity and viral replication in the respiratory tract. The study is currently available on the bioRxiv* preprint server.

27 Jul 2021

A novel interferon-γ release assay for detection of SARS-CoV-2 specific T-cell response

A new study evaluates a commercially available IFN‐γ release assay (IGRA) to determine T-cell responses targeted against SARS-CoV-2.

26 Jul 2021

Researchers develop new exosome formulation to deliver VEGF antibodies for synergistic therapy

Researchers from the Institute of Process Engineering of the Chinese Academy of Sciences, Beijing Chaoyang Hospital and the University of Queensland have developed a new formulation based on regulatory T-cell exosomes (rEXS) to deliver vascular endothelial growth factor (VEGF) antibodies for choroidal neovascularization therapy.

26 Jul 2021

SARS-CoV-2 antibodies in breast milk: Study

A new study published on the medRxiv* preprint server explores the presence of immunoglobulin (Ig) antibodies IgA and IgG against SARS-CoV-2 in breast milk secreted by women with confirmed infection. The scientists also delineated the specific antigens targeted by the antibodies.

26 Jul 2021

Study compares mRNA and adenovirus-based SARS-CoV-2 vaccines against variants of concern

In a research paper recently uploaded to the preprint server bioRxiv by Tada et al. (July 19th, 2021) the neutralizing capacity of antibodies generated by either messenger RNA (mRNA) or adenoviral vector-based vaccines against Beta, Delta, Delta plus, and Lambda variants are investigated, among others, highlighting the importance of continued SARS-CoV-2 genomic surveillance.

26 Jul 2021

Novel atlas charts how different antibodies attack a major piece of SARS-CoV-2 machinery

As the SARS-CoV-2 virus that causes COVID-19 continues to evolve, immunologists and infectious diseases experts are eager to know whether new variants are resistant to the human antibodies that recognized initial versions of the virus.

26 Jul 2021

5.6% seroprevalence of SARS-CoV-2 antibodies in England during second wave

A recent study conducted as a part of the Real-Time Assessment of Community Transmission-2 (REACT-2) program has estimated the seroprevalence of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies among adult populations in England.

25 Jul 2021

CD8+ T cells show gene-dependent variation in cross-reactivity to human coronaviruses

A new study discusses how both different responses to the infection itself and to COVID-19 vaccines are likely the result of genetic differences.

25 Jul 2021

Study receives $15 million CDC award to continue research on COVID-19 immunity, vaccine effectiveness

A University of Arizona Health Sciences study of COVID-19 vaccine effectiveness and immunity among frontline workers has received a $15 million award from the U.S. Centers for Disease Control and Prevention (CDC) to continue the current research for another year and expand to include children and focus on underserved populations.

23 Jul 2021

Research uncovers an unexpected role for immune T cells in protection against malaria

Advanced technologies have been used to solve a long-standing mystery about why some people develop serious illness when they are infected with the malaria parasite, while others carry the infection asymptomatically.

23 Jul 2021

Advantages and challenges of intranasal vaccines to fight against COVID-19 infections

There are many reasons that an intranasal vaccine against the SARS-CoV-2 virus would be helpful in the fight against COVID-19 infections, University of Alabama at Birmingham immunologists Fran Lund, Ph.D., and Troy Randall, Ph.D., write in a viewpoint article in the journal Science.

23 Jul 2021

Researchers discover camelid-derived two nanobodies that target SARS-CoV-2

A new study has been published on the bioRxiv* preprint server, which has identified and characterized two RBD-targeting neutralizing nanobodies, namely, DL4 and DL28.

23 Jul 2021

Clinical trials during a pandemic – lessons from COVID-19

In this interview, Dr. Benedicte Roquebert, Dr. Stephanie Haim-Boukobza and Dr. Souad Mehlal discuss how COVID-19 has resulted in new ways to think about clinical trials during a pandemic.

From Cerba Research 23 Jul 2021

SARS-COV-2 infection leads to neutralizing and protective serological responses in over 70% of DPs

Iain Chapple, University of Birmingham, England, presented the oral session "Longitudinal Serological and Vaccination Responses to SARS-COV-2 in Dental Professionals" at the virtual 99th General Session & Exhibition of the International Association for Dental Research (IADR), held in conjunction with the 50th Annual Meeting of the American Association for Dental Research (AADR) and the 45th Annual Meeting of the Canadian Association for Dental Research (CADR), on July 21-24, 2021.

23 Jul 2021

Synergistic multi-antibody cocktail protects against SARS-CoV-2 in animal model

Researchers in Canada have reported the discovery of a multi-antibody cocktail that synergistically protected against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in an animal model of acute infection.

22 Jul 2021

Innovative testing platform could enable more precise, personalized immunotherapy

An innovative testing platform that more closely mimics what cancer encounters in the body may allow for more precise, personalized therapies by enabling the rapid study of multiple therapeutic combinations against tumor cells.

22 Jul 2021

Llama ‘nanobodies’ have the potential to outwit human cytomegalovirus

Scientists have developed a 'nanobody' - a small fragment of a llama antibody - that is capable of chasing out human cytomegalovirus (HCMV) as it hides away from the immune system.

22 Jul 2021

Study in France suggests high efficacy of mRNA vaccines against SARS-CoV-2 variants of concern

A nationwide case-control study conducted in France has assessed the efficacy of mRNA-based coronavirus disease 2019 (COVID-19) vaccines against original severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its variants, including B.1.1.7, B.1.351, and P1.

22 Jul 2021

Antibodies News and Research

Impaired immune response to SARS-CoV-2 mRNA vaccination in immunocompromised patients

PerkinElmer to Acquire Antibody and Reagent Leader BioLegend

Monoclonal antibody CT-P59 demonstrates potent antiviral efficacy against SARS-CoV-2 delta variant

A novel interferon-γ release assay for detection of SARS-CoV-2 specific T-cell response

Researchers develop new exosome formulation to deliver VEGF antibodies for synergistic therapy

SARS-CoV-2 antibodies in breast milk: Study

Study compares mRNA and adenovirus-based SARS-CoV-2 vaccines against variants of concern

Novel atlas charts how different antibodies attack a major piece of SARS-CoV-2 machinery

5.6% seroprevalence of SARS-CoV-2 antibodies in England during second wave

CD8+ T cells show gene-dependent variation in cross-reactivity to human coronaviruses

Study receives $15 million CDC award to continue research on COVID-19 immunity, vaccine effectiveness

Research uncovers an unexpected role for immune T cells in protection against malaria

Advantages and challenges of intranasal vaccines to fight against COVID-19 infections

Researchers discover camelid-derived two nanobodies that target SARS-CoV-2

Clinical trials during a pandemic – lessons from COVID-19

SARS-COV-2 infection leads to neutralizing and protective serological responses in over 70% of DPs

Synergistic multi-antibody cocktail protects against SARS-CoV-2 in animal model

Innovative testing platform could enable more precise, personalized immunotherapy

Llama ‘nanobodies’ have the potential to outwit human cytomegalovirus

Study in France suggests high efficacy of mRNA vaccines against SARS-CoV-2 variants of concern

eBook: End-to-end solutions for bispecific antibody development eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo